论文部分内容阅读
采用放免法检测了６０例大肠癌和１５例大t肠良性病变患者血清β＿２－微球蛋白含量。大肠癌患者为４．５１±１．６２ｕｇ／ｍｌ，大肠良性病变患者为２．９３±０．７７ｕｇ／ｍｌ。两者之间有显著差异（Ｐ＜０．０５）。Ａ、Ｂ期患者血清β＿２－微珠蛋白值为４．０５±２．４ｕｇ／ｍｌ．Ｃ、Ｄ期患者血清β＿２－微球蛋白值为４．９３±０．８４ｕｇ／ｍｌ。后者高于前者（Ｐ＜０．０５）．结果提示：血清β＿２－微球蛋白水平与大肠肿瘤良、恶性及大肠癌分期有关，测定血清β＿２－在球蛋白含量对鉴别诊断和病情估计有一定的临床意义。
Radioimmunoassay was used to detect serum β 2 -microglobulin levels in 60 patients with colorectal cancer and 15 patients with large intestinal lesions. The colorectal cancer patients were 4.51±1.62ug/ml, and the colorectal benign lesions were 2.93±0.77ug/ml. There was a significant difference between the two (P<0.05). The serum β 2 -microglobin value in patients with stage A and B was 4.05±2.4ug/ml. The serum β2-microglobulin values in patients with stage C and D were 4.93±0.84ug/ml. The latter is higher than the former (P<0.05). The results suggest that serum β 2 -microglobulin levels are associated with benign, malignant and colorectal cancer stages of colorectal tumors. Determination of serum β 2 -globulin content has some clinical significance in differential diagnosis and disease estimation.